On May 2, 2022, Abbott Laboratories announced that at its annual general meeting of shareholder held on April 29, 2022, the shareholders rejected a shareholder proposal that the Company's Board of Directors adopt a policy on Rule 10b5-1 plans with certain restrictions and disclosure requirements.